

Approved



**Cote d'Ivoire**  
**Country Operational Plan**  
**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		129,821		129,821	209,590	339,411
USAID		46,579,857		46,579,857	5,452,656	52,032,513
DOD		2,115,716		2,115,716	65,000	2,180,716
HHS/CDC	1,775,000	77,291,404		79,066,404	6,398,764	85,465,168
HHS/HRSA		112,500		112,500	0	112,500
State/AF		50,000		50,000	0	50,000
<b>Total</b>	<b>1,775,000</b>	<b>126,279,298</b>	<b>0</b>	<b>128,054,298</b>	<b>12,126,010</b>	<b>140,180,308</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	State/AF	USAID		
HBHC		44,419	4,539,479		12,500	3,003,886	0	7,600,284
HKID			7,817,853			3,773,192	0	11,591,045
HLAB		304,200	5,284,865			247,277	0	5,836,342
HMBL			68,826				0	68,826
HMIN			24,285				0	24,285
HTXD			24,285			14,425,730	0	14,450,015
HTXS		805,825	31,331,605			7,849,890	0	39,987,320
HVAB			291,991			65,917	0	357,908
HVCT		464,872	4,886,031		25,000	2,770,349	0	8,146,252
HVMS	129,821	37,700	7,591,010			2,438,807	0	10,197,338
HVOP		219,600	2,773,997		12,500	2,391,545	0	5,397,642
HVSI		234,900	913,215			1,297,982	0	2,446,097

Approved



HVTB			3,660,519			20,646	0	<b>3,681,165</b>
MTCT			3,692,856			477,166	0	<b>4,170,022</b>
OHSS		4,200	620,537	0		6,607,195	0	<b>7,231,932</b>
PDCS			2,335,154			1,029,939	0	<b>3,365,093</b>
PDTX			3,209,896	112,500		180,336	0	<b>3,502,732</b>
	<b>129,821</b>	<b>2,115,716</b>	<b>79,066,404</b>	<b>112,500</b>	<b>50,000</b>	<b>46,579,857</b>	<b>0</b>	<b>128,054,298</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	7,450,406	0
HKID	11,444,515	0
HVTB	3,614,567	0
PDCS	3,169,336	0
<b>Total Technical Area Planned Funding:</b>	<b>25,678,824</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	4,901,225	0
HVSI	1,742,121	0
OHSS	7,022,263	0
<b>Total Technical Area Planned Funding:</b>	<b>13,665,609</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMIN	0	0
HVAB	295,665	0
HVCT	8,020,894	0
HVOP	5,228,475	0
MTCT	4,058,913	0
<b>Total Technical Area Planned Funding:</b>	<b>17,603,947</b>	<b>0</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	14,241,822	0
HTXS	39,333,850	0
PDTX	3,396,047	0
<b>Total Technical Area Planned Funding:</b>	<b>56,971,719</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	515,832
	Number of new ANC and L&D clients	541,223
	By: Known positives at entry	6,409
	By: Number of new positives identified	9,273
	Sum of Positives Status disaggregates	15,682
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	0
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	515,832
	New on ART	8,615
	Already on ART at beginning of current pregnancy	6,423
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	204,915
	Total number of people in the target population	2,929,834
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	



	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	0
	Aggregated Age/sex: 15+ Male	123,443
	Aggregated Age/sex: <15 Female	0
	Aggregated Age/sex: 15+ Female	81,472
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	n/a



	minimum standards required (DSD)	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	68,714
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	662
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,540
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	26
	By key population type: Transgender who are NOT sex workers (Numerator: Number of	26



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	55,465
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	0



	minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	



	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,314,736
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	0
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex:		



	Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex:	



	Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	69,914
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	583,547
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	66,665
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	594,574
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	3,938
	Test Result by Aggregated Age and Sex: Positive 15+ Male	25,999
	Test Result by Aggregated Age and Sex: Positive <15 Female	3,529
	Test Result by Aggregated Age and Sex: Positive 15+ Female	26,392
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	0
	Age/sex: 1-9	0
	Service Delivery Point	30,585



	(Community): Index testing	
	Service Delivery Point	0
	(Community): Homebased testing	
	Service Delivery Point	17,260
	(Community): Mobile testing	
	Service Delivery Point	166,439
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	499,815
	Service Delivery Point (Facility): Outpatient	58,771
	Service Delivery Point (Facility): Pediatric	0
	Service Delivery Point (Facility): Malnutrition facilities	9,989
	Service Delivery Point (Facility): Other PITC	0
	Service Delivery Point (Facility):	0



VCT	
Service Delivery Point (Facility): VMMC	0
Service Delivery Point (Facility): PMTCT	508,826
Service Delivery Point (Facility): TB Clinics	22,598
Service Delivery Point (Facility): Index testing	490
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	22,561
	Total number of registered new and relapsed TB cases, during the reporting period.	24,519
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24	



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	542
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,004
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	361
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9,754
	Result: Known HIV positive at service entry	



	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,021
	Age/Sex: <10 Male	0
	Age/Sex: 10-14 Male	0



	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	0
	Age/Sex: 25-49 Male	0
	Age/Sex: 50+ Male	0
	Age/Sex: <10 Female	0
	Age/Sex: 10-14 Female	14
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	50
	Age/Sex: 25-49 Female	332
	Age/Sex: 50+ Female	2
	Sum of Age/Sex Disaggregates	14
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	693
	By type of service: Sexual Violence (Post-Rape Care)	321
	By PEP service provision (related to sexual violence services provided)	236
	Age/Sex: 15-19 Female	25
	Age/Sex: 15-19 male	0
GEND_GB_V_TA	Number of people receiving post-GBV care	
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 20-24 Female	



	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	0
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	
	By type of service: Sexual Violence (Post-Rape Care)	
	By PEP service provision (related to sexual violence services provided)	
	Age/Sex: 15-19 Female	
	Age/Sex: 15-19 Male	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	228,862
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	26,078
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	49,882
	Sum of Age/Sex disaggregates	75,960
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and	



	sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and	



	sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS	



	countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening	



	Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS	



	countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	10,558
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	9,787
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



	Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	32,615
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	3,786
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
	Age/Sex: 18+ Female	7,088
	Sum of Age/Sex disaggregates	10,874



	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male	



	1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Parenting/Caregiver Program Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	



	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	



	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a



	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,465
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,696
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and	



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	42
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,845
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	65
	Aggregated Age/Sex: Female 15+	2,543



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	184,644
	Screened for TB by Age/Sex: <15 Male	4,744
	Screened for TB by Age/Sex: 15+ Male	49,150
	Screened for TB by Age/Sex: <15 Female	4,648
	Screened for TB by Age/Sex: 15+ Female	126,111
	Screen Result: Screened Positive for TB	18,448
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	18,447
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	13,965



	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,348
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	2,083
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	8,614
	By infants who received their first virologic HIV test between 2 and 12 months of age	4,317
	Sum of Infant Age disaggregates	12,931
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	198
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative	



	virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	299
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	206,312
	Age/Sex: 15-19 Male	244
	Age/Sex: 15-19 Female	678
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	7,211
	Aggregated Age/Sex: 15+ Male	64,359
	Aggregated Age/Sex: <15 Female	6,982
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	127,721
	Sum of Aggregated Age/Sex <15	14,193
	Sum of Aggregated Age/Sex 15+	192,080
	Sum of Aggregated Age/Sex disaggregates	206,273
	Age/Sex: <1	531
	Age/Sex: <1-9	2,865
	Age/Sex: 10-14 Male	683
	Age/Sex: 10-14 Female	627
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	563
	Age/Sex: 25-49 Male	17,252
	Age/Sex: 50+ Male	4,901
	Age/Sex: 20-24 Female	2,895



	Age/Sex: 25-49 Female	37,139
	Age/Sex: 50+ Female	4,822
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	78,626
	By Age/Sex: <1	353
	By Age/Sex: 1-9	1,876
	By Age/Sex: 10-14 Male	467
	By Age/Sex: 15-19 Male	261
	By Age/Sex: 20-24 Male	261
	By Age/Sex: 25-49 Male	6,882
	By Age/Sex: 50+ Male	2,176
	By Age/Sex: 10-14 Female	410
	By Age/Sex: 15-19 Female	261
	By Age/Sex: 20-24 Female	1,083
	By Age/Sex: 25-49 Female	14,711
	By Age/Sex: 50+ Female	1,945
	Sum of Age/Sex disaggregates	28,457
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	3,775
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	22,552
	Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	3,641	
Aggregated Grouping by Age/Sex: 15+ Female	42,938	



	Sum of Aggregated Age/Sex disaggregates	72,906
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	166,438
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	218,981
	Numerator: Indication: Routine	25,545
	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication:	



	<1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication:	



	25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	34,058
	Denominator: Indication: Targeted	0
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by	



	Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by	



	Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex	



	by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	5,432
	Numerator Aggregated Age/Sex: 15+ Male	51,723
	Numerator Aggregated Age/Sex: <15 Female	5,285
	Numerator Aggregated Age/Sex: 15+ Female	102,652
	Denominator Aggregated Age/Sex: <15 Male	7,273
	Denominator Aggregated Age/Sex: 15+ Male	68,604
	Denominator Aggregated Age/Sex: <15 Female	7,072
	Denominator Aggregated Age/Sex: 15+ Female	136,037
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	35,815
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	44,772
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60



	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	422
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	97
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	41
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	118
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,843
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,236
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	90
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	149
	Age/Sex: 20-24 Female	654



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,235
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,138
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	79
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	563
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	124
	Age/Sex: 15-19 Male	58



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	160
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,790
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,484
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	120



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	201
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	819
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,310
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,384
	Aggregated Age: <15 (Numerator:	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	641
	Aggregated Age/Sex: 15+ Male	10,857



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	630
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21,148
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	850
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,504
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	843



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26,407
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	123
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	414
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	340
	CD4: Number of laboratories that perform this testing	
	CD4: Number of laboratories that participate in this PT program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that perform this	9



	testing	
	Early infant diagnostics: Number of laboratories that participate in this PT program	9
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	HIV viral load: Number of laboratories that perform this testing	10
	HIV viral load: Number of laboratories that participate in this PT program	10
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	10
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	124
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	36
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	36
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	7
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	7
	TB diagnostics (Xpert MTB/RIF):	7



	Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	2
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	2
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2,509
	By Graduates: Doctors	350
	By Graduates: Nurses	1,090
	By Graduates: Midwives	685
	By Graduates: Social service workers	248
	By Graduates: Laboratory professionals	136
	By Graduates: Other	
	Sum of Graduates disaggreagtes	2,509
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	22
	Number of HIV Test Kits purchased	2
	Number of HIV CD4 Reagents	1



	purchased	
	Number of Condoms purchased	2
	Number of HIV Viral Load Reagents purchased	1
	Number of HIV ARVs purchased	16
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	2,478,113
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	366,440
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	6,682,290
	Condoms: Dollars planned (COP)/ spent (Actual)	300,000
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9419	International Lab Coalition	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,943,076
10141	Pasteur Institute of Ivory Coast	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
11491	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,701,831
12673	Ministry of Health and Public Hygiene, Cote d'Ivoire	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0



			Prevention		
12679	Ministry of Family, Women, and Social Affairs, Cote d'Ivoire	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12803	Heartland Alliance	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13272	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13525	Hope Cote d'Ivoire	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13539	International Rescue Committee	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



13561	ACONDA	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,675,479
13602	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	282,180
13616	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13624	Sante Espoir Vie - Cote d'Ivoire	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,230,178
13631	Fondation Ariel Glaser Pour la Lutte Contre le Sida Pediatrique en Cote D'Ivoire	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,769,250
13651	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
14073	TBD	TBD	Redacted	Redacted	Redacted
14122	FHI 360	NGO	U.S. Agency for International Development	GHP-State	475,000
16685	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	704,161
16691	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development	GHP-State	2,041,730
16747	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	700,000
16861	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	571,021
17003	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	112,500
17014	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	50,000



			Control and Prevention		
17494	Health Alliance International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,145,103
17496	Population Services International	NGO	U.S. Department of Defense	GHP-State	2,050,716
17515	Save The Children Federation Inc	NGO	U.S. Agency for International Development	GHP-State	5,254,869
17583	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	787,749
17584	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17602	UNICEF	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	179,670
17610	Aga Khan Foundation	NGO	U.S. Agency for International	GHP-State	0



			Development		
17763	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,568,896
17872	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	422,650
17903	Emory University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17914	TBD	TBD	Redacted	Redacted	Redacted
17942	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	1,600,001
18287	TBD	TBD	Redacted	Redacted	Redacted
18288	TBD	TBD	Redacted	Redacted	Redacted
18289	TBD	TBD	Redacted	Redacted	Redacted
18290	TBD	TBD	Redacted	Redacted	Redacted
18291	TBD	TBD	Redacted	Redacted	Redacted
18292	TBD	TBD	Redacted	Redacted	Redacted
18293	TBD	TBD	Redacted	Redacted	Redacted
18294	TBD	TBD	Redacted	Redacted	Redacted
18295	TBD	TBD	Redacted	Redacted	Redacted
18296	TBD	TBD	Redacted	Redacted	Redacted
18377	TBD	TBD	Redacted	Redacted	Redacted
18378	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	18,203,684
18382	TBD	TBD	Redacted	Redacted	Redacted
18399	U.S. Department	Other USG	U.S. Department	GHP-State	50,000



	of State	Agency	of State/Bureau of African Affairs		
18423	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	1,943,102
18431	UNAIDS II	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
18435	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 9419</b>	<b>Mechanism Name: CDC Lab Coalition</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Lab Coalition	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,943,076</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,943,076</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,943,076

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Renovation	60,000
Motor Vehicles: Purchased	40,000

### Budget Code Information

<b>Mechanism ID: 9419</b>			
<b>Mechanism Name: CDC Lab Coalition</b>			
<b>Prime Partner Name: International Lab Coalition</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	300,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,443,076	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,400,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10141</b>	<b>Mechanism Name: Building Capacity of the Pasteur Institute to Provide Quality Laboratory Diagnosis and Surveillance of Opportunistic Infections Related to HIV in the Republic of Cote d'Ivoire (Institut Pasteur)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pasteur Institute of Ivory Coast	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount



GHP-State	0
-----------	---

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10141		
<b>Mechanism Name:</b>	Building Capacity of the Pasteur Institute to Provide Quality Laboratory Diagnosis and Surveillance of Opportunistic Infections Related to HIV in		
<b>Prime Partner Name:</b>	the Republic of Cote d'Ivoire (Institut Pasteur) Pasteur Institute of Ivory Coast		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 11491</b>	<b>Mechanism Name: CDC-RETRO-CI GHAI</b>
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
<b>Total All Funding Sources: 2,701,831</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,701,831</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,701,831

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	11491		
<b>Mechanism Name:</b>	CDC-RETRO-CI GHAI		
<b>Prime Partner Name:</b>	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	105,792	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	105,792	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	1,311,149	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Treatment	HTXS	829,098	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12673</b>	<b>Mechanism Name: Ministry of Health 2010 CoAg</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Public Hygiene, Cote d'Ivoire	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12673		
<b>Mechanism Name:</b>	Ministry of Health 2010 CoAg		
<b>Prime Partner Name:</b>	Ministry of Health and Public Hygiene, Cote d'Ivoire		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12679</b>	<b>Mechanism Name: MFFAS-PNOEV CoAg 2010</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Family, Women, and Social Affairs, Cote d'Ivoire	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC



<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12679		
<b>Mechanism Name:</b>	MFFAS-PNOEV CoAg 2010		
<b>Prime Partner Name:</b>	Ministry of Family, Women, and Social Affairs, Cote d'Ivoire		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12803</b>	<b>Mechanism Name: IMPACT-CI IMPROVING</b>
----------------------------	--



<b>PREVENTION AND ACCESS TO CARE AND TREATMENT-COTE D'IVOIRE (Heartland HVP 2010 CDC CoAg)</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Heartland Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12803		
<b>Mechanism Name:</b>	IMPACT-CI IMPROVING PREVENTION AND ACCESS TO CARE AND TREATMENT-COTE D'IVOIRE (Heartland HVP 2010 CDC CoAg)		
<b>Prime Partner Name:</b>	Heartland Alliance		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,418
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	70
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,523
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4
KP_PREV_DSD	By key population type: Female sex workers (FSW)	6,814



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,525
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,002
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,523
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,525
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,525
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	181
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	498
HTC_TST_DSD	Service Delivery Point (Community): Index testing	555
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
HTC_TST_DSD	Service Delivery Point (Community): Other	4,970

**Implementing Mechanism Details**

<b>Mechanism ID: 13272</b>	<b>Mechanism Name: EGPAF OVC-AB 2010 CDC Coag-Keneya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 13272			
<b>Mechanism Name:</b> EGPAF OVC-AB 2010 CDC Coag-Keneya			
<b>Prime Partner Name:</b> Elizabeth Glaser Pediatric AIDS Foundation			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,447
PP_PREV_DSD	Total number of people in the target population	77,168
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	3,581
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,866
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,205
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	842
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,785
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	883
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,695
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,725
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,480
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	7,205
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	51
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	119
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	52
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	127



	Female	
HTC_TST_DSD	Service Delivery Point (Community): Index testing	1,183
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
HTC_TST_DSD	Service Delivery Point (Community): Other	6,022
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,752
OVC_SERV_DSD	Age/Sex: 18+ Male	1,149
OVC_SERV_DSD	Age/Sex: 18+ Female	2,106
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,255
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,204
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,293

**Implementing Mechanism Details**

<b>Mechanism ID: 13525</b>	<b>Mechanism Name: Hope CI OVC-AB 2010 CDC CoAg</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope Cote d'Ivoire	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 13525			
<b>Mechanism Name:</b> Hope CI OVC-AB 2010 CDC CoAg			
<b>Prime Partner Name:</b> Hope Cote d'Ivoire			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,684
PP_PREV_DSD	Total number of people in the target population	159,048
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	7,852
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	3,832
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,427
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	722
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,253
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	794
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,621
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,516
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	9,874
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	11,390
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	47
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	215



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	49
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	202
HTC_TST_DSD	Service Delivery Point (Community): Index testing	1,559
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
HTC_TST_DSD	Service Delivery Point (Community): Other	9,868
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,757
OVC_SERV_DSD	Age/Sex: 18+ Male	988
OVC_SERV_DSD	Age/Sex: 18+ Female	1,933
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,921
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,828
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,018

**Implementing Mechanism Details**

<b>Mechanism ID: 13539</b>	<b>Mechanism Name: IRC 2010 CDC Coag</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Rescue Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13539			
<b>Mechanism Name:</b> IRC 2010 CDC Coag			
<b>Prime Partner Name:</b> International Rescue Committee			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,413
PP_PREV_DSD	Total number of people in the target population	28,954
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	5,776
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,637
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,605
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	688
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,473
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	720
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,724
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,408
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,197
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	8,605
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	41



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	163
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	42
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	150
HTC_TST_DSD	Service Delivery Point (Community): Index testing	1,235
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
HTC_TST_DSD	Service Delivery Point (Community): Other	7,370
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,956
OVC_SERV_DSD	Age/Sex: 18+ Male	891
OVC_SERV_DSD	Age/Sex: 18+ Female	1,764
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,655
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,443
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	2,858

**Implementing Mechanism Details**

<b>Mechanism ID: 13561</b>	<b>Mechanism Name: ACONDA CoAg 2011</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: ACONDA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,675,479</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,675,479</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,675,479



**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	2,013,558
Food and Nutrition: Policy, Tools, and Service Delivery	15,000
Food and Nutrition: Commodities	15,000
Economic Strengthening	10,000
Education	10,000
Water	10,000
Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b> 13561			
<b>Mechanism Name:</b> ACONDA CoAg 2011			
<b>Prime Partner Name:</b> ACONDA			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	706,243	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	433,559	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	180,717	0
Governance and Systems	HLAB	40,000	0
Prevention	HVCT	220,468	0
Prevention	MTCT	378,888	0
Treatment	HTXS	4,017,860	0
Treatment	PDTX	697,744	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	66,732
PMTCT_ART_DSD	New on ART	1,493
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,092
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	66,732
PMTCT_STAT_DSD	Number of new ANC and L&D clients	70,200
PMTCT_STAT_DSD	By: Known positives at entry	1,092
PMTCT_STAT_DSD	By: Number of new positives identified	1,621



PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,713
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	154,722
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,024
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	73,441
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,453
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	67,804
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	13,477
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	141,245
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	154,722
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	372
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,991
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	321
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,761
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	74,116
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	8,714
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	1,483
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	65,900
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	4,509
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,509
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,677
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,450
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	65
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,967
GEND_GBV_DSD	Number of people receiving post-GBV care	212
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	158
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	54
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	44
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	779
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	820
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	239

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	536
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	36,279
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	931
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	9,649
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	911
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	24,788
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,629
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,629
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,750
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	459
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	420
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,480
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	738
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,218
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	38
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	59



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	40,312
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,596
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,443
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,534
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	24,739
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,130
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	37,182
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	40,312
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	20,474
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,089
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	6,273
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,055
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	12,057
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	20,474
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	34,657
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	43,493
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,205
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	10,357
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,178
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	20,571
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,599
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	13,504
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,544
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	26,846
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,504



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,884
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	68
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,824
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	68
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,544
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	92
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,271
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	4,427



	stopped ART, and those lost to follow-up)	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	28
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	28
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	28
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	3
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	30
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	9
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of	2



	laboratories that achieve acceptable successful passing criteria in this PT program	
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

**Implementing Mechanism Details**

<b>Mechanism ID: 13602</b>	<b>Mechanism Name: LMG (Leadership, Management and Governance Project)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 282,180</b>	
<b>Applied Pipeline Amount: 225,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 507,180</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	282,180

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13602
----------------------------



<b>Mechanism Name:</b>	<b>LMG (Leadership, Management and Governance Project)</b>		
<b>Prime Partner Name:</b>	<b>Management Sciences for Health</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	282,180	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13616</b>	<b>Mechanism Name: Columbia University ICAP - CDC CoAg 2011</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**



<b>Mechanism ID:</b> 13616			
<b>Mechanism Name:</b> Columbia University ICAP - CDC CoAg 2011			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status	51,045



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	1,001
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	559
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,045
PMTCT_STAT_DSD	Number of new ANC and L&D clients	52,167
PMTCT_STAT_DSD	By: Known positives at entry	546
PMTCT_STAT_DSD	By: Number of new positives identified	1,046
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,592
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	80,441
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,694
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	38,157
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,379
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	35,211
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,073
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	73,368
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	80,441
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	253
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,590
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	190
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,464
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	24,944



HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	2,954
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	520
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	50,415
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,581
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,620
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,658
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	909
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	634
GEND_GBV_DSD	Number of people receiving post-GBV care	107
GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	0
GEND_GBV_DSD	Age/Sex: 20-24 Male	0
GEND_GBV_DSD	Age/Sex: 25-49 Male	0
GEND_GBV_DSD	Age/Sex: 50+ Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	0
GEND_GBV_DSD	Age/Sex: 10-14 Female	0



GEND_GBVDSD	Age/Sex: 20-24 Female	13
GEND_GBVDSD	Age/Sex: 25-49 Female	89
GEND_GBVDSD	Age/Sex: 50+ Female	0
GEND_GBVDSD	Sum of Age/Sex Disaggregates	0
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	67
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	39
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	41
GEND_GBVDSD	Age/Sex: 15-19 Female	5
GEND_GBVDSD	Age/Sex: 15-19 male	0
GEND_GBVTa	Age/Sex: 50+ Female	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	214
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	221
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	97
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	108

TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	13,142
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	380
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	3,498
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	378
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	8,886
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,311
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,311
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	999
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	190
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	165
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	870
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	462
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,332
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	37
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	42
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,720
TX_NEW_DSD	By Age/Sex: <1	93
TX_NEW_DSD	By Age/Sex: 1-9	419
TX_NEW_DSD	By Age/Sex: 10-14 Male	108
TX_NEW_DSD	By Age/Sex: 15-19 Male	61
TX_NEW_DSD	By Age/Sex: 20-24 Male	61
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,241



TX_NEW_DSD	By Age/Sex: 50+ Male	378
TX_NEW_DSD	By Age/Sex: 10-14 Female	94
TX_NEW_DSD	By Age/Sex: 15-19 Female	61
TX_NEW_DSD	By Age/Sex: 20-24 Female	215
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,635
TX_NEW_DSD	By Age/Sex: 50+ Female	354
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,208
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	11,754
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,323
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	456
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,664
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	440
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	7,194
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	587
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	4,847
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	573
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	9,565
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,532
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,150
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	79



TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	596
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	209
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	110
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,242
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	183
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14



TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	108
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	731
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	251
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of	43



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	137
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,551
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	216
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	32
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	32
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	26
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1



LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	20
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	8
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

### Implementing Mechanism Details

<b>Mechanism ID: 13624</b>	<b>Mechanism Name: SEV-CI CDC CoAg 2011</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Sante Espoir Vie - Cote d'Ivoire	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 5,230,178</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,230,178</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,230,178

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	4,080,555
Food and Nutrition: Policy, Tools, and Service Delivery	313,889
Food and Nutrition: Commodities	156,944
Water	52,315
Renovation	171,000
Gender: GBV	52,315
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	13624		
<b>Mechanism Name:</b>	SEV-CI CDC CoAg 2011		
<b>Prime Partner Name:</b>	Sante Espoir Vie - Cote d'Ivoire		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	496,085	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HKID	416,028	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	309,685	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	154,423	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	32,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	299,206	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	543,621	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,382,907	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	596,223	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,191
PMTCT_ART_DSD	New on ART	1,081
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	921



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,191
PMTCT_STAT_DSD	Number of new ANC and L&D clients	100,135
PMTCT_STAT_DSD	By: Known positives at entry	921
PMTCT_STAT_DSD	By: Number of new positives identified	1,170
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,091
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	213,570
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,217
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	100,680
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,469
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	93,204
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	19,686
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	193,884
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	213,570
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	554
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,105
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	473
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,802
HTC_TST_DSD	Age/sex: 1-9	0
HTC_TST_DSD	Service Delivery Point (Community): Index testing	568
HTC_TST_DSD	Service Delivery Point (Community): Other	1,709
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	100,859



HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	11,858
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	2,022
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	94,000
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,554
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,554
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,718
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	73
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,447
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	40
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	994
GEND_GBV_DSD	Number of people receiving post-GBV care	137
GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	0
GEND_GBV_DSD	Age/Sex: 20-24 Male	0
GEND_GBV_DSD	Age/Sex: 25-49 Male	0
GEND_GBV_DSD	Age/Sex: 50+ Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	0
GEND_GBV_DSD	Age/Sex: 10-14 Female	3



GEND_GBV_DSD	Age/Sex: 20-24 Female	10
GEND_GBV_DSD	Age/Sex: 25-49 Female	116
GEND_GBV_DSD	Age/Sex: 50+ Female	1
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	3
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	106
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	29
GEND_GBV_DSD	Age/Sex: 15-19 Female	6
GEND_GBV_DSD	Age/Sex: 15-19 male	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,230
OVC_SERV_DSD	Age/Sex: 18+ Male	832
OVC_SERV_DSD	Age/Sex: 18+ Female	1,577
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,409
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,436
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	2,385
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	547
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	575
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	222
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	16



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	302
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	27,475
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	696
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	7,329
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	683
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	18,767
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,741
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,741
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,096
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	344
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	301
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,159
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	578
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,737
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	22
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	34
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	30,544



TX_CURR_DSD	Age/Sex: 15-19 Male	99
TX_CURR_DSD	Age/Sex: 15-19 Female	280
TX_CURR_DSD	Sum of age/sex disaggregates	379
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,199
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,457
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,158
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	18,730
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,357
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	28,187
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	30,544
TX_CURR_DSD	Age/Sex: <1	263
TX_CURR_DSD	Age/Sex: <1-9	1,434
TX_CURR_DSD	Age/Sex: 10-14 Male	347
TX_CURR_DSD	Age/Sex: 10-14 Female	313
TX_CURR_DSD	Age/Sex: 20-24 Male	232
TX_CURR_DSD	Age/Sex: 25-49 Male	7,093
TX_CURR_DSD	Age/Sex: 50+ Male	2,033
TX_CURR_DSD	Age/Sex: 20-24 Female	1,191
TX_CURR_DSD	Age/Sex: 25-49 Female	15,276
TX_CURR_DSD	Age/Sex: 50+ Female	1,983
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,907
TX_NEW_DSD	By Age/Sex: <1	169
TX_NEW_DSD	By Age/Sex: 1-9	943
TX_NEW_DSD	By Age/Sex: 10-14 Male	232
TX_NEW_DSD	By Age/Sex: 15-19 Male	98
TX_NEW_DSD	By Age/Sex: 20-24 Male	98
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,871
TX_NEW_DSD	By Age/Sex: 50+ Male	867
TX_NEW_DSD	By Age/Sex: 10-14 Female	205
TX_NEW_DSD	By Age/Sex: 15-19 Female	98
TX_NEW_DSD	By Age/Sex: 20-24 Female	444



TX_NEW_DSD	By Age/Sex: 25-49 Female	6,109
TX_NEW_DSD	By Age/Sex: 50+ Female	773
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,795
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	790
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,934
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	759
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,424
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,907
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	24,034
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	32,057
TX_PVLS_DSD	Numerator: Indication: Routine	24,034
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	32,057
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	885
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,478
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	868
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	14,803
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,202
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	9,938
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,164
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	19,753
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,557
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,949



TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	108
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,347
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	437
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	48
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	226
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,883
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	395



	months after initiating ART	
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	149
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	53
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,679
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	525



TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	62
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	282
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,618
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	487
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	85
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,836
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	84
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	3,552



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	112
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,276
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	112
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,449
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	26
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	26
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	21
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this	1



	PT program	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	19
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

### Implementing Mechanism Details

<b>Mechanism ID: 13631</b>	<b>Mechanism Name: Fondation Ariel CDC CoAg 2011</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Fondation Ariel Glaser Pour la Lutte Contre le Sida Pediatrique en Cote D'Ivoire	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,769,250</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,769,250</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,769,250

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	120,000
Human Resources for Health	1,132,777

**Budget Code Information**

<b>Mechanism ID:</b>	13631		
<b>Mechanism Name:</b>	Fondation Ariel CDC CoAg 2011		
<b>Prime Partner Name:</b>	Fondation Ariel Glaser Pour la Lutte Contre le Sida Pediatrique en Cote D'Ivoire		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	555,682	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	690,503	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	454,205	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	94,602	0
Governance and Systems	HLAB	32,000	0
Prevention	HVCT	236,216	0
Prevention	MTCT	570,095	0
Treatment	HTXS	2,770,696	0
Treatment	PDTX	365,251	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	84,027
PMTCT_ART_DSD	New on ART	1,292
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,010
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	84,027
PMTCT_STAT_DSD	Number of new ANC and L&D clients	88,394
PMTCT_STAT_DSD	By: Known positives at entry	1,010
PMTCT_STAT_DSD	By: Number of new positives identified	1,390



PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,400
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	174,310
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,788
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	81,573
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,187
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	75,762
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	16,975
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	157,335
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	174,310
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	490
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,342
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	487
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,095
HTC_TST_DSD	Service Delivery Point (Community): Index testing	948
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
HTC_TST_DSD	Service Delivery Point (Community): Other	2,833
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	71,835
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	8,447
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	1,436
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0



HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	82,768
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	6,043
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6,043
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	6,397
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	181
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,584
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	100
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,178
GEND_GBV_DSD	Number of people receiving post-GBV care	180
GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	0
GEND_GBV_DSD	Age/Sex: 20-24 Male	0
GEND_GBV_DSD	Age/Sex: 25-49 Male	0
GEND_GBV_DSD	Age/Sex: 50+ Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	0
GEND_GBV_DSD	Age/Sex: 10-14 Female	11
GEND_GBV_DSD	Age/Sex: 20-24 Female	27
GEND_GBV_DSD	Age/Sex: 25-49 Female	127
GEND_GBV_DSD	Age/Sex: 50+ Female	1
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	11



GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	122
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	58
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	46
GEND_GBVDSD	Age/Sex: 15-19 Female	14
GEND_GBVDSD	Age/Sex: 15-19 male	0
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,000
OVC_SERVDSD	Age/Sex: 18+ Male	1,335
OVC_SERVDSD	Age/Sex: 18+ Female	2,659
OVC_SERVDSD	Sum of Age/Sex disaggregates	3,994
OVC_SERVDSD	By Aggregated Age/Sex: <18 Male	3,859
OVC_SERVDSD	By Aggregated Age/Sex: <18 Female	4,147
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,633
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,718
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	19
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	712
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	879

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	38,385
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	974
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	10,243
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	957
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	26,220
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,817
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,817
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,920
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	467
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	430
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,300
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	678
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,978
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	32
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	52
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	42,656
TX_CURR_DSD	Age/Sex: 15-19 Male	145
TX_CURR_DSD	Age/Sex: 15-19 Female	398
TX_CURR_DSD	Sum of age/sex disaggregates	543
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,196



TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,503
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,153
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	26,804
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,349
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	40,307
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	42,656
TX_CURR_DSD	Age/Sex: <1	268
TX_CURR_DSD	Age/Sex: <1-9	1,431
TX_CURR_DSD	Age/Sex: 10-14 Male	336
TX_CURR_DSD	Age/Sex: 10-14 Female	314
TX_CURR_DSD	Age/Sex: 20-24 Male	331
TX_CURR_DSD	Age/Sex: 25-49 Male	10,159
TX_CURR_DSD	Age/Sex: 50+ Male	2,868
TX_CURR_DSD	Age/Sex: 20-24 Female	1,704
TX_CURR_DSD	Age/Sex: 25-49 Female	21,863
TX_CURR_DSD	Age/Sex: 50+ Female	2,839
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,059
TX_NEW_DSD	By Age/Sex: <1	91
TX_NEW_DSD	By Age/Sex: 1-9	514
TX_NEW_DSD	By Age/Sex: 10-14 Male	127
TX_NEW_DSD	By Age/Sex: 15-19 Male	102
TX_NEW_DSD	By Age/Sex: 20-24 Male	102
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,770
TX_NEW_DSD	By Age/Sex: 50+ Male	931
TX_NEW_DSD	By Age/Sex: 10-14 Female	111
TX_NEW_DSD	By Age/Sex: 15-19 Female	102
TX_NEW_DSD	By Age/Sex: 20-24 Female	424
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,967
TX_NEW_DSD	By Age/Sex: 50+ Female	818
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,454
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	431



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,905
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	412
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,311
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,059
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	33,474
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	44,686
TX_PVLS_DSD	Denominator: Indication: Routine	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	906
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	10,610
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	883
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	21,075
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,208
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	14,158
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,183
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	28,137
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,996
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,993
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	235
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	49



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	59
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,900
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	590
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	73
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	318
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,110
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	560
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	45
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	306



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	77
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,380
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	708
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	96



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	400
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,141
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	681
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	187
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,568
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	178
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,056
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	245
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	3,205



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	236
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,289
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	28
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	28
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	23
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	3
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3



LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	27
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	13
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	13
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

**Implementing Mechanism Details**

<b>Mechanism ID: 13651</b>	<b>Mechanism Name: EGPAF international CDC CoAg 2011-Djidja</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13651			
<b>Mechanism Name:</b> EGPAF international CDC CoAg 2011-Djidja			
<b>Prime Partner Name:</b> Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,421
PMTCT_ART_DSD	New on ART	838
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	592
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,421
PMTCT_STAT_DSD	Number of new ANC and L&D clients	42,514
PMTCT_STAT_DSD	By: Known positives at entry	616
PMTCT_STAT_DSD	By: Number of new positives identified	891
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,507
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	65,235
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,002
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,934
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,749



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,550
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,751
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	59,484
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	65,235
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	213
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,297
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	157
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,194
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	20,428
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	2,433
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	444
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	39,914
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,016
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,068
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,513
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,192



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	39
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	771
GEND_GBV_DSD	Number of people receiving post-GBV care	105
GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	0
GEND_GBV_DSD	Age/Sex: 20-24 Male	0
GEND_GBV_DSD	Age/Sex: 25-49 Male	0
GEND_GBV_DSD	Age/Sex: 50+ Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	0
GEND_GBV_DSD	Age/Sex: 50+ Female	0
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	0
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	68
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	37
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	37
GEND_GBV_DSD	Age/Sex: 15-19 male	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	288
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	303
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	118



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	164
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	14,989
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	419
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	4,005
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	416
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	10,149
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,490
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,490
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,086
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	219
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	185
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	842
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	398
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,240
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	36
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	41



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,459
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	217
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,408
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	215
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,619
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,459
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	13,434
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	17,548
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	422
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	4,242
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	412
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	8,358
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	553
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	5,623
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	538
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	10,834
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,623
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,507
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	108
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,163



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	108
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,244
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	138
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,438
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	139
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,792

### Implementing Mechanism Details

<b>Mechanism ID: 14073</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 14122</b>	<b>Mechanism Name: FANTA3 (Food and Nutrition Technical Assistance)</b>
----------------------------	---



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 475,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 475,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	475,000

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	1
---	---

**Budget Code Information**

<b>Mechanism ID:</b>	14122		
<b>Mechanism Name:</b>	FANTA3 (Food and Nutrition Technical Assistance)		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	75,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	100,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16685</b>	<b>Mechanism Name: HFG (Health Finance and Governance)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 704,161</b>	
<b>Applied Pipeline Amount: 181,250</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 885,411</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	704,161

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	10
----------------------------	----

**Budget Code Information**

<b>Mechanism ID: 16685</b>
<b>Mechanism Name: HFG (Health Finance and Governance)</b>



<b>Prime Partner Name: Abt Associates</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	554,161	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	150,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2,125
HRH_PRE	By Graduates: Doctors	350
HRH_PRE	By Graduates: Nurses	1,090
HRH_PRE	By Graduates: Midwives	685
HRH_PRE	Sum of Graduates disaggreagtes	2,125

### Implementing Mechanism Details

<b>Mechanism ID: 16691</b>	<b>Mechanism Name: HC3</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,041,730</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,041,730</b>	
Funding Source	Funding Amount



GHP-State	2,041,730
-----------	-----------

**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	1,000,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Condom programming	10,000
Motor Vehicles: Purchased	40,000
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients

**Budget Code Information**

<b>Mechanism ID:</b>	16691		
<b>Mechanism Name:</b>	HC3		
<b>Prime Partner Name:</b>	Johns Hopkins University Bloomberg School of Public Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVAB	28,043	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	170,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,093,687	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	600,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	74,782
PP_PREV_DSD	Total number of people in the target population	1,207,814
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	33,652
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	41,130

### Implementing Mechanism Details

<b>Mechanism ID: 16747</b>	<b>Mechanism Name: JHPIEGO CoAg 2013</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Approved



<b>Total All Funding Sources: 700,000</b>	
<b>Applied Pipeline Amount: 322,436</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,022,436</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	700,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	400,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 16747</b>			
<b>Mechanism Name: JHPIEGO CoAg 2013</b>			
<b>Prime Partner Name: JHPIEGO</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	700,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16861</b>	<b>Mechanism Name: ASSIST</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 571,021</b>	
<b>Applied Pipeline Amount: 229,358</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 800,379</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	571,021

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16861</b>			
<b>Mechanism Name: ASSIST</b>			
<b>Prime Partner Name: University Research Corporation, LLC</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	19,565	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	86,239	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	465,217	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key	1



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1

**Implementing Mechanism Details**

<b>Mechanism ID: 17003</b>	<b>Mechanism Name: HRSA Columbia Global Nurse Capacity Building Program 2013</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 112,500</b>	
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 112,500</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	112,500

### Cross-Cutting Budget Attribution(s)

Education	45,000
-----------	--------

### Budget Code Information

<b>Mechanism ID:</b> 17003			
<b>Mechanism Name:</b> HRSA Columbia Global Nurse Capacity Building Program 2013			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	112,500	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17014	<b>Mechanism Name:</b> FHI360_ Surveillance and Program Evaluation
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 50,000</b>	
<b>Applied Pipeline Amount: 1,926,148</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,976,148</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	50,000

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	40,000
Human Resources for Health	10,000

**Budget Code Information**

<b>Mechanism ID: 17014</b>			
<b>Mechanism Name: FHI360_ Surveillance and Program Evaluation</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17494</b>	<b>Mechanism Name: HAI coag2015</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Alliance International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,145,103</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,145,103</b>	
Funding Source	Funding Amount
GHP-State	5,145,103

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	4,580,761
Renovation	275,000



Motor Vehicles: Purchased	114,000
Gender: GBV	154,408
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b> 17494			
<b>Mechanism Name:</b> HAI coag2015			
<b>Prime Partner Name:</b> Health Alliance International			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	472,303	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	581,058	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	268,394	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	121,829	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	32,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	377,944	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	593,041	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,228,156	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	470,378	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	80,270
PMTCT_ART_DSD	New on ART	1,068
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,096
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	80,270
PMTCT_STAT_DSD	Number of new ANC and L&D clients	84,453
PMTCT_STAT_DSD	By: Known positives at entry	1,070
PMTCT_STAT_DSD	By: Number of new positives identified	1,147
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,217
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	266,216
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,825
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	125,407



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,870
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	116,114
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	24,695
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	241,521
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	266,216
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	699
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	5,118
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	583
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,740
HTC_TST_DSD	Service Delivery Point (Community): Index testing	795
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
HTC_TST_DSD	Service Delivery Point (Community): Other	2,387
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	159,441
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	18,751
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	3,192
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	79,326
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,324
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,286
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	2,434



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	69
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,291
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	42
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	884
GEND_GBV_DSD	Number of people receiving post-GBV care	184
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	142
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	42
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	39
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,098
OVC_SERV_DSD	Age/Sex: 18+ Male	1,750
OVC_SERV_DSD	Age/Sex: 18+ Female	1,614
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,364
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,378
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,356
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	635
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	666
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The	7

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	293
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	355
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	27,322
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	702
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	7,268
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	684
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	18,668
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,736
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,736
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,068
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	364
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	304
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,276
PMTCT_EID_DSD	By infants who received their first virologic HIV test	644



	between 2 and 12 months of age	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,920
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	22
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	34
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	30,784
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,156
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,552
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,142
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	18,934
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,298
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	28,486
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	30,784
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,551
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	767
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,786
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	737
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,261
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,551
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	25,042
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	33,388
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	887
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,808
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	858
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	15,489



TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,191
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	10,404
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,161
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	20,632
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,106
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,379
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	101
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,686
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	97
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,222
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	139
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,085
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	138



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	291
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	233
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	2
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	2
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	27
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3



LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

**Implementing Mechanism Details**

<b>Mechanism ID: 17496</b>	<b>Mechanism Name: PSI Cote d'Ivoire</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,050,716</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,050,716</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,050,716

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 17496			
<b>Mechanism Name:</b> PSI Cote d'Ivoire			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	41,619	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	230,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	460,672	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	215,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	803,025	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	14,360
PP_PREV_DSD	Total number of people in the target population	40,000



PP_PREV_DSD	Aggregated Age/sex: 15+ Male	11,488
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,872
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,260
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	46
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,780
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,421
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	59
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,201
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	17,260
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	739
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	121
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	17,260
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	3
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3

## Implementing Mechanism Details



<b>Mechanism ID: 17515</b>	<b>Mechanism Name: REVE Reducing Vulnerability in Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Save The Children Federation Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,254,869</b>	
<b>Applied Pipeline Amount: 350,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,604,869</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,254,869

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	33,000
Economic Strengthening	500,000
Education	10,000
Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	200,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	40,000

**Budget Code Information**

<b>Mechanism ID:</b>	17515		
<b>Mechanism Name:</b>	REVE Reducing Vulnerability in Children		
<b>Prime Partner Name:</b>	Save The Children Federation Inc		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	49,090	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	3,689,018	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	69,333	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	221,173	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	68,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,158,255	0



## Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,661
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,588
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,593
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,944
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,536
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,532
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	12,129
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	27,661
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	456
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	276
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	478
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	450
HTC_TST_DSD	Service Delivery Point (Community): Index testing	6,917
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
HTC_TST_DSD	Service Delivery Point (Community): Other	20,744
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	87,760



	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 18+ Male	9,532
OVC_SERV_DSD	Age/Sex: 18+ Female	19,723
OVC_SERV_DSD	Sum of Age/Sex disaggregates	29,255
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	29,142
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	29,363

**Implementing Mechanism Details**

<b>Mechanism ID: 17583</b>	<b>Mechanism Name: Measure Evaluation Phase IV</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 787,749</b>	
<b>Applied Pipeline Amount: 112,251</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 900,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	787,749

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17583		
<b>Mechanism Name:</b>	Measure Evaluation Phase IV		
<b>Prime Partner Name:</b>	University of North Carolina at Chapel Hill, Carolina Population Center		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	787,749	0
------------------------	------	---------	---

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17584</b>	<b>Mechanism Name: HIV Impact Assessment (HIA)</b>
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 458,575</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 458,575</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17584			
<b>Mechanism Name:</b> HIV Impact Assessment (HIA)			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Governance and Systems	HVSI	0	0
------------------------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17602</b>	<b>Mechanism Name: New CDC Award to UNICEF</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 179,670</b>	
<b>Applied Pipeline Amount: 141,605</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 321,275</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	179,670

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 17602</b>			
<b>Mechanism Name: New CDC Award to UNICEF</b>			
<b>Prime Partner Name: UNICEF</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Care	HKID	179,670	0
------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17610</b>	<b>Mechanism Name: Telemedicine in Côte d'Ivoire</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Aga Khan Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17610		
<b>Mechanism Name:</b>	Telemedicine in Côte d'Ivoire		
<b>Prime Partner Name:</b>	Aga Khan Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	OHSS	0	0



Systems			
---------	--	--	--

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 17763</b>	<b>Mechanism Name: LINKAGES</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,568,896</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,568,896</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,568,896

## Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	40,000
Key Populations: MSM and TG	700,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	350,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on



	sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	30,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation

**Budget Code Information**

<b>Mechanism ID: 17763</b>			
<b>Mechanism Name: LINKAGES</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	33,992	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	26,853	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	365,766	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,047,262	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	75,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	1,020,023	0
-----------	------	-----------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	30,689
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	355
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,742
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	23,566



	the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,100
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,460
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,640
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	20,100
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,100
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	803
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,719
HTC_TST_DSD	Service Delivery Point (Community): Index testing	2,011
HTC_TST_DSD	Service Delivery Point (Community): Other	18,089

### Implementing Mechanism Details

<b>Mechanism ID: 17872</b>	<b>Mechanism Name: Global Health Supply Chain Quality Assurance</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Approved



<b>Total All Funding Sources: 422,650</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 422,650</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	422,650

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17872		
<b>Mechanism Name:</b>	Global Health Supply Chain Quality Assurance		
<b>Prime Partner Name:</b>	Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	422,650	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17903</b>	<b>Mechanism Name: African Health Profession Regulatory Collaborative for Nurses and Midwives (ARC)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Emory University	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17903		
<b>Mechanism Name:</b>	African Health Profession Regulatory Collaborative for Nurses and		
<b>Prime Partner Name:</b>	Midwives (ARC)		
	Emory University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17914</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



**Implementing Mechanism Details**

<b>Mechanism ID: 17942</b>	<b>Mechanism Name: PRIVATE SECTOR HEALTH PROJECT</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,600,001</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,600,001</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,600,001

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17942		
<b>Mechanism Name:</b>	PRIVATE SECTOR HEALTH PROJECT		
<b>Prime Partner Name:</b>	Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	60,657	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	20,646	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	PDCS	7,857	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	15,748	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	82,367	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,282,390	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	30,336	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,920
PMTCT_ART_DSD	New on ART	147
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	104
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,920
PMTCT_STAT_DSD	Number of new ANC and L&D clients	7,286
PMTCT_STAT_DSD	By: Known positives at entry	104
PMTCT_STAT_DSD	By: Number of new positives identified	166
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	270



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,212
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	473
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,846
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	419
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,474
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	892
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	9,320
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	10,212
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	32
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	201
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	13
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	180
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	2,966
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	349
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	59
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	6,838
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	145
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	78
PMTCT_EID_DSD	Sum of Infant Age disaggregates	223
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result	0



	within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	716
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	250
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	460
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	710
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	716
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,202
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	26
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	417
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	23
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	736
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,202

**Implementing Mechanism Details**

<b>Mechanism ID: 18287</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18288</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18289</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



### Implementing Mechanism Details

Mechanism ID: 18290	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18291	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18292	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18293	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18294	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18295	TBD: Yes
REDACTED	

### Implementing Mechanism Details



<b>Mechanism ID: 18296</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18377</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18378</b>	<b>Mechanism Name: Global Health Supply Chain-Procurement and Supply Management (GHSC-PSM, TO1),</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 18,203,684</b>	
<b>Applied Pipeline Amount: 3,000,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 21,203,684</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	18,203,684

**Cross-Cutting Budget Attribution(s)**

Condom procurement	300,000
Condom programming	10,000



**Budget Code Information**

<b>Mechanism ID:</b>	18378		
<b>Mechanism Name:</b>	Global Health Supply Chain-Procurement and Supply Management		
<b>Prime Partner Name:</b>	(GHSC-PSM, TO1), Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	402,749	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	252,749	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	14,241,822	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,156,364	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18382</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18399</b>	<b>Mechanism Name: Small Grants Program</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 50,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	50,000

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	50,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Key Populations: FSW	12,500
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	12,500
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Economic Strengthening	20,000

**Budget Code Information**

<b>Mechanism ID: 18399</b>
----------------------------



<b>Mechanism Name:</b> Small Grants Program			
<b>Prime Partner Name:</b> U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	12,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	12,500	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18423</b>	<b>Mechanism Name: Global Health Supply Chain - Rapid Test Kits</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,943,102</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,943,102</b>	
Funding Source	Funding Amount
GHP-State	1,943,102

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18423			
<b>Mechanism Name:</b> Global Health Supply Chain - Rapid Test Kits			
<b>Prime Partner Name:</b> Global Health Supply Chain Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,943,102	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18431	<b>Mechanism Name:</b> CDC UNAIDS Central Mechanism
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS II	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 100,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 100,000	
Funding Source	Funding Amount
GHP-State	100,000

**Cross-Cutting Budget Attribution(s)**

Education	25,000
-----------	--------



**Budget Code Information**

<b>Mechanism ID:</b>	18431		
<b>Mechanism Name:</b>	CDC UNAIDS Central Mechanism		
<b>Prime Partner Name:</b>	UNAIDS II		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18435</b>	<b>Mechanism Name: UCSF SI/M&amp;E/Surveillance TA - Central mechanism</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

**Cross-Cutting Budget Attribution(s)**



(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18435			
<b>Mechanism Name:</b> UCSF SI/M&E/Surveillance TA - Central mechanism			
<b>Prime Partner Name:</b> University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	50,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Agency Information - Costs of Doing Business  
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		26,533		7,473	26,533	34,006
ICASS		870,561		245,205	870,561	1,115,766
Institutional Contractors		244,601		68,895	244,601	313,496



Management Meetings/Professional Development		124,581		35,089	124,581	159,670
Non-ICASS Administrative Costs		26,533		7,473	26,533	34,006
Staff Program Travel		90,378		25,456	90,378	115,834
USG Staff Salaries and Benefits - Internationally Recruited		1,528,933		432,923	1,528,933	1,961,856
USG Staff Salaries and Benefits - Locally Recruited		655,258		182,283	655,258	837,541
<b>Total</b>	<b>0</b>	<b>3,567,378</b>	<b>0</b>	<b>1,004,797</b>	<b>3,567,378</b>	<b>4,572,175</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		25,000		0	25,000	25,000
Management Meetings/Profes		5,000		0	5,000	5,000



sional Development						
Staff Program Travel		0		20,000	0	20,000
USG Staff Salaries and Benefits - Locally Recruited		35,000		45,000	35,000	80,000
<b>Total</b>	<b>0</b>	<b>65,000</b>	<b>0</b>	<b>65,000</b>	<b>65,000</b>	<b>130,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

<b>Agency Cost of Doing Business</b>	<b>GAP</b>	<b>GHP-State</b>	<b>GHP-USAID</b>	<b>Applied Pipeline</b>	<b>Total</b>	<b>Total All Cost of Doing Business Categories and Applied Pipeline Amount</b>
Capital Security Cost Sharing		1,200,000		0	1,200,000	1,200,000
Computers/IT Services		390,000		0	390,000	390,000
ICASS	367,100	1,632,900		0	2,000,000	2,000,000
Institutional Contractors		340,000		0	340,000	340,000
Management Meetings/Professional Development	125,000	279,000		80,000	404,000	484,000
Non-ICASS	352,900	385,000		187,427	737,900	925,327



Administrative Costs						
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel	100,000	254,100		85,000	354,100	439,100
USG Staff Salaries and Benefits - Internationally Recruited	830,000			90,000	830,000	920,000
USG Staff Salaries and Benefits - Locally Recruited		4,116,000		57,573	4,116,000	4,173,573
<b>Total</b>	<b>1,775,000</b>	<b>8,597,000</b>	<b>0</b>	<b>500,000</b>	<b>10,372,000</b>	<b>10,872,000</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Indirect Costs		34,584		0	34,584	34,584
Management Meetings/Professional Development		0		25,000	0	25,000
Non-ICASS		21,241		43,759	21,241	65,000

Approved



Administrative Costs						
Staff Program Travel		0		7,871	0	7,871
USG Staff Salaries and Benefits - Internationally Recruited		73,996		132,960	73,996	206,956
USG Staff Salaries and Benefits - Locally Recruited		0		0	0	0
<b>Total</b>	<b>0</b>	<b>129,821</b>	<b>0</b>	<b>209,590</b>	<b>129,821</b>	<b>339,411</b>